Navigation Links
Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
Date:8/22/2011

and/or the EMA, that CTI may not receive an opinion regarding approvability of pixantrone from the CHMP in the first  quarter of 2012, that the CHMP may request additional information from CTI regarding pixantrone, that CTI may not receive a positive opinion from the CHMP, that CTI may not be able to commence commercialization of pixantrone in the first half 2012, that CTI may not resubmit the NDA for approval to the FDA during the fourth quarter of 2011, that the FDA's review of the NDA may take longer than six months, that the FDA may not approve the NDA as early as April 2012 or at all, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com

Investors Contact:
Ed Bell
T: 206.272.4345
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors

Medical Information Contact:
T: 800.715.0944
E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
2. Echo Therapeutics Announces Second Quarter 2011 Financial Results
3. Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
4. Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription
5. Echo Therapeutics Unveils Symphony tCGM Demonstration Video
6. Orexigen® Therapeutics Reports Second Quarter Ended June 30, 2011 Financial Results
7. Echo Therapeutics Announces Multiple Patents and Trademark Grants
8. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
9. Silence Therapeutics Receives Notice of Allowance for New U.S. Patent Covering Novel Small Interfering RNA (siRNA) Delivery Technology
10. Prefilled Syringes: Devices, Therapeutics, Players, Markets and Prospects
11. Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  EMD Serono, Inc., a subsidiary of ... today that Drew Young has joined the ... this capacity, he will be responsible for leading the ... including future products.   Bringing more than 20 ... sales efforts at pharmaceutical and biotech companies, Mr. Young ...
(Date:9/2/2014)... 2014  Cyberonics, Inc. (NASDAQ: CYBX ... study.  Results of the study presented by a ... cardiology congress and concurrently published by the ... Therapy (ART) in patients with moderate to severe ... safe, improves the heart,s ability to pump blood, ...
(Date:9/2/2014)... , Sept. 2, 2014 ResMed (NYSE: ... 150 devices in the United States ... portable, lightweight, and user-friendly life support ventilators. ... mobility and ease of use for patients suffering from ... adult and childhood respiratory disorders. The U.S. launch comes ...
Breaking Medicine Technology:EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 2ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 3
... Formation in ... Animals, Hearts, SUNRISE, ... of myoblasts modified to express,stromal derived factor-1(alpha) protein (SDF-1) into the ... were recently,presented at two scientific meetings -- the International Society for,Magnetic ...
... Enrollment Program Speeds Oncology Patient Accrual, ... Research Management,Organization (RMO), has contracted with five ... management services for their,clinical trials using the ... the following disease indications: follicular Non-Hodgkin,s,Lymphoma, Metastatic ...
Cached Medicine Technology:Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 2Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 3Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 4Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 5Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2
(Date:9/2/2014)... Boca Raton, FL (PRWEB) September 02, 2014 ... online audience targeting and multi-channel email marketing is pleased ... to the market, Firearms & Freedom as ... these online properties represent more than one million concerned ... and display advertising. , “We are honored to ...
(Date:9/2/2014)... patient adherence to treatment following a myocardial infarction ... results reported at the European Society of Cardiology,s ... Principal Investigator Valentin Fuster, MD, PhD, Director of ... at Mount Sinai and General Director of the ... in Madrid, Spain, the novel fixed-dose combination drug ...
(Date:9/2/2014)... of California, San Diego School of Medicine have identified ... The findings, reported in the current issue of ... cancer mortality worldwide. An estimated 40,000 women in America ... the American Cancer Society. , "The take-home message of ... to target breast cancer metastasis through a pathway regulated ...
(Date:9/2/2014)... associated with many health risks, including heart disease and ... possible way to mitigate one often-overlooked risk: not buckling ... by Sheldon H. Jacobson, a professor of computer science ... are associated with a decrease in seatbelt usage. However, ... in effect. , "Primary seatbelt laws lead to increased ...
(Date:9/2/2014)... 02, 2014 To commemorate the 13th ... children’s literacy organization that has donated more than 200,000 ... founding in 2001, will host the 5th Annual BJF ... p.m. at Barnes & Noble Tribeca. Featuring special guest ... public event for children and families will celebrate the ...
Breaking Medicine News(10 mins):Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Enzyme controlling metastasis of breast cancer identified 2Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Brooke Jackman Foundation Hosts 5th Annual Read-A-Thon, A Celebration of Hope and Literacy in New York City to Commemorate 13th Anniversary of 9/11 2Health News:Brooke Jackman Foundation Hosts 5th Annual Read-A-Thon, A Celebration of Hope and Literacy in New York City to Commemorate 13th Anniversary of 9/11 3
... , TUESDAY, Sept. 27 (HealthDay News) -- Men may need ... suggests. The study found that men were far more ... adenomas) in their colon -- 24.9 percent of men compared ... at an earlier age. "In our study, analysis of ...
... Discussing and documenting patients, preferences for care at the end ... recent claims. A new study published today in the ... with their physicians about end-of-life care and have an advance ... patients who do not have these discussions and documents. ...
... Steven Reinberg HealthDay Reporter , TUESDAY, Sept. 27 ... to an enlarged prostate, saw palmetto extract doesn,t seem to ... at high doses, a new study finds. Many men ... relieve lower urinary tract symptoms related to benign prostatic hyperplasia ...
... been honored with the Presidential Early Career Award ... and scientific leadership. It is the highest honor ... engineering professionals in the early stages of their ... Sept. 26. Justin Kasper, an astrophysicist at ...
... TUESDAY, Sept. 27 (HealthDay News) -- Average annual premiums for ... past year, to more than $15,000, according to new research ... Educational Trust. On average, U.S. workers now pay more ... has far outpaced growth in workers, wages, the 2011 employer ...
... an associate professor in the department of mathematical ... Arts, has received the honor of "Excellence in ... Convocation at NJIT traditionally honors select faculty ... level of excellence over a sustained period. ...
Cached Medicine News:Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 2Health News:Do Men Need Colon Cancer Screening Earlier Than Women Do? 3Health News:Saw Palmetto Doesn't Help Enlarged Prostate: Study 2Health News:Saw Palmetto Doesn't Help Enlarged Prostate: Study 3Health News:President Barack Obama recognizes outstanding scientists at the Smithsonian 2Health News:Cost of U.S. Workers' Health Premiums Surged in 2011 2Health News:Cost of U.S. Workers' Health Premiums Surged in 2011 3Health News:Gifted mathematician honored at NJIT convocation 2
... DXC-990 camera is a 3 chip 1/2 inch color ... and a high s/n ratio. It offers picture contrast ... and knee control. The user can choose automatic exposure ... The Sony DXC-990 camera is a bayonet mount and ...
Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
... image management. Mediscan is an advanced ... derived from extensive experience with clinicians. ... organize, and distribute high quality images, ... effort. Can be connected to flexible ...
For continuous intracranial monitoring of pressure, oxygen and temperature of the brain...
Medicine Products: